Gene therapies offer a new method of potential treatment, particularly for patients with rare genetic diseases. Whether you’re developing a viral vector-based therapy, such as an adeno-associated virus (AAV) or lentivirus (lenti) product, or applying gene editing technologies such as CRISPR/cas9, you’ll benefit from our Expert Teams’ deep knowledge and experience.
Assess safety, establish proof of concept and feasibility to support IND/IMPD/CTA submissions, and rapidly transition to first-in-human trials
In vitro and in vivo pharmacology disease model development
Advanced therapy development solutions
Connect With Us
New cell and gene therapy suite
Cell and gene therapies are incredibly intricate, but they’re making a huge difference in the drug development market and in the lives of patients. Learn all about our $9.2 million investment in cell and gene therapy.
REDEFINING WHAT’S POSSIBLE FOR YOUR STUDIES
We’ve invested more than $700 million in scientific innovations to advance your nonclinical studies. With our expanded lab space, newest technologies and digitized back offices, the solutions we provide are more innovative than ever.
Labcorp is a leading global life sciences company that includes contract research and developmental services to the pharmaceutical, medical technology, crop protection and chemical industries.
.png){kind=icon}
